Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical (Takeda) has signed an agreement with Janssen Pharmaceutical and Janssen Pharmaceutica regarding co-marketing of Galantamine (R113675) in Japan.
Subscribe to our email newsletter
Galantamine is a drug for Alzheimer’s disease and chemically known as galantamine hydrobromide (hereinafter called galantamine).
Following the development of Galantamine by Janssen Pharmaceutica, for the treatment of Alzheimer’s Disease in Japan, Janssen Pharma has submitted an application for approval to the Ministry of Health, Labor and Welfare in February 2010.
Once approved, Takeda and Janssen Pharma are expected to co-market Galantamine under the same brand name.
As per the agreement, Takeda has received rights to co-market Galantamine in Japan, and will make an upfront contractual payment, as well as launch and annual sales milestone payments to Janssen Pharma and Janssen Pharmaceutica. In addition, Takeda will pay a fixed rate based on sales. Other contractual details are not disclosed.
For Takeda, the agreement is expected to expand and improve its domestic pipeline in CNS (central nervous system) which is one of Takeda’s core therapeutic disease areas.
Takeda said that after receiving approval, they are looking forward to offer a new treatment option for patients suffering from Alzheimer’s Disease, their families and healthcare professionals.